The {pharmaceutical sector is currently exploring novel treatment strategies for obesity , and the emergence of semaglutide 10mg doses represents a significant advancement . Clinicians are now assess the possible benefits and challenges associated with this increased concentration version , notably in comparison to existing less potent semaglutide